MAT Waiver Training Parts 1 & 2
Event Details
MAT Waiver Training Parts 1 & 2
06/28 - 06/30/2021
1:00 pm - 5:00 pm
ZOOM Webinar
Phoenix, Arizona, 85004
Event Description
To prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder, physicians are required to complete 8 hours of training in order to apply to the Drug Enforcement Agency for a waiver. This two part free course will provide prescribers with the 8 hours of required MAT training. Following completion of the course, attendees will be given a link to complete the remainder of the training at no cost from the Providers Clinical Support System (PCSS). Nurse Practitioners (NP) and Physician assistants (PA) are required to complete 24 hours of training including the 8 hour MAT training.

Part 1 will be held June 28th from 1-5pm

Part 2 will be held June 30th from 1-5pm

Registration: Free

At the conclusion of this activity participants should be able to:
• Screen and identify patients with OUD and define evidence-based treatments.
• Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
• Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
• Explain the process of buprenorphine induction as well as stabilization and maintenance.
• Discuss all FDA approved antagonist and agonist medications to treat OUD.
• Discuss basic office protocols including medical record documentation and confidentially.
• Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
• Recognize the importance of obtaining a waiver to begin treating patients with OUD.

This event has been approved by the Office of Continuing Medical Education and has been awarded a maximum of 8 AMA PRA Category 1 Credit(s). Please contact with any questions.

Accreditation and Continuing Education Information

American Academy of Addiction Psychiatry is the Data Sponsor for this training. Funding for this course was made possible (in part) by 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Additional Funding Attribution: Arizona State Opioid Response (SOR) grant, Arizona Health Care Cost Containment System, Substance Abuse and Mental Health Services Administration, grant #T1081709-01.